Ac immune acquires affiris' specific active immunotherapy (sait) anti-alpha-synuclein programs targeting neurodegenerative diseases

Vienna, austria, july 27, 2021 (globe newswire) -- affiris ag, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying specific active immunotherapies (saits), today announced that ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring affiris' anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. all acquired programs are based on affiris´ affitome® technology.
ACIU Ratings Summary
ACIU Quant Ranking